期刊文献+

非布司他联合秋水仙碱治疗高尿酸血症伴痛风的临床效果 被引量:2

下载PDF
导出
摘要 目的 探讨非布司他联合秋水仙碱治疗高尿酸血症伴痛风的效果及其对细胞黏附因子1水平的影响。 方法 选取2016年2月至2018年6月在本院门诊就诊的高尿酸血症伴痛风患者110例。应用随机数字表法将患者随机分为对照组与观察组,各55例。对照组患者口服秋水仙碱和别嘌呤片,观察组患者口服非布司他和秋水仙碱。比较两组患者治疗后临床疗效。 结果 对照组与观察组治疗24周尿酸水平分别为(475.63±74.19)、(458.62±80.33)(μmol/L),与治疗前比较,两组尿酸水平均显著降低(P<0.05)。对照组与观察组治疗24周sICAM-1水平为(369.19±86.37)、(333.09±72.66)(ng/L),与治疗前比较,两组细胞黏附因子1(sICAM-1)水平均显著降低;与对照组治疗24周比较,观察组sICAM-1水平显著降低,差异均有统计学意义(P<0.05)。两组患者治疗前后肝功能指标谷丙转氨酶(ALT)、谷草转氨酶(AST)及肾功能指标(Cr)、尿素氮(BUN)均无显著变化(P>0.05)。 结论 非布司他联合秋水仙碱治疗高尿酸血症伴痛风,可显著降低尿酸及血管内皮素-1水平。
出处 《浙江创伤外科》 2019年第3期522-523,共2页 Zhejiang Journal of Traumatic Surgery
  • 相关文献

参考文献5

二级参考文献42

  • 1FILIOPOULOS V, HADJIYANNAKOS D, VLASSOPOULOSD. New insights into uric acid effects on the progression andprognosis of chronic kidney disease [J]. Ren Fail,2012,34(4):510-520.
  • 2WEINER DE, TIGHIOUART H,ELSAYED E F, et al. Uricacid and incident kidney disease in the community [J], J AmSoc Nephrol,2008,19 (6) : 1204-1211.
  • 3TERKELTAUB R, BUSHIUSKY DA, BECKER MA. Recentdevelopments in our understanding of the renal basis ofhyperuricemia and the development of novel antihyperuricemictherapeutics [J], Arthritis Res Ther, 2006, 8 (suppl) : S4.
  • 4CHAO J, TERKELTAUB R. A critical reappraisal ofallopurinol dosing, safety, and efficacy for hyperuricemia ingout [J]. Rheumato Rep, 2009,11 (2) : 135-140.
  • 5TAYAR JH, LOPEZ - OLIV 0 MA, Suarez - Almazor. Febuxostatfor treating chronic gout [J]. Cochrane Database Syst Rev,2012,14 (1):11.
  • 6ISEKI K, IKEMIYA Y,INOUE T, et al. Significance ofhyperuricemia as a risk factor for developing ESRD in ascreened cohort [J]. Am J Kidney Dis,2004,44(4) :642-650.
  • 7CHONCHOL M, SHLIPAK MG, KATZ R, et al. Relationshipof uric acid with progression of kidney disease [J]. Am JKidney Dis ,2007, 50 (2) :239-247.
  • 8SIU YP, LEUNG KT, TONG MK, et al. Use of allopurinol inslowing the progression of renal disease through its ability tolower serum uric acid level [ J ]. Am J Kidney Dis,2006,47?1):51-59.
  • 9SHIBAGAKI Y, OHNO I’ HOSOYA T, et al. Safety,efficacy and renal effect of febuxostat in patients withmoderate -to - severe kidney dysfunction [J]. Hypertens Res,2014,37(10):919-925.
  • 10SIRCAR D,CHATTERJEE S,WAIKHOM H, et al. Efficacyof Febuxostat for Slowing the GFR Decline in Patients WithCKD and Asymptomatic Hyperuricemia : A 6-Month, Double-Blind, Randomized, Placebo - Controlled Trial [J].Am JKidney Dis, 2015,66(6) :945-950.

共引文献240

同被引文献12

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部